"Pacritinib Offers New Option For Patients With Advanced Myelofibrosis" - Katie Kosko
Findings from a phase 3 randomized clinical trial offer new hope to some patients who have advanced myelofibrosis (MF), a type of myeloproliferative neoplasm (MPN), which are blood cancers collectively. Results from the study show the pacritinib is safe and effective in the treatment of patients with advanced MF who also have thrombocytopenia. “This trial was important as it demonstrated that in a population with very advanced disease as measured by significant thrombocytopenia that limits the ability to effectively receive Jakafi, or have previously failed Jakafi, pacritinib was effective in reducing spleen size and improving symptom burden at the dose of 200 mg twice daily,” said John Mascarenhas, MD, associate professor of medicine, hematology and medical oncology, director of the adult leukemia program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “Importantly, almost half the patients had received Jakafi previously and half that were randomized to best available therapy received Jakafi. This further highlights the unmet need and lack of effective therapies for this patient population,” he added.
- John O. Mascarenhas, MD, Associate Professor, Medicine, Hematology and Medical Oncology, Director, Adult Leukemia Program, Leader, Clinical Investigation within Myeloproliferative Disorders Program, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Additional coverage:
Oncology Nursing News